乙型肝炎病毒感染合并非酒精性脂肪性肝病：相互作用与预后
Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis.
作者信息
Liu Lili, Li Hong, Zhang Yang, Zhang Jing, Cao Zhenhuan
机构信息
The Third Unit, Department of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Biomedical Information Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
出版信息
Heliyon. 2023 Jan 20;9(1):e13113. doi: 10.1016/j.heliyon.2023.e13113. eCollection 2023 Jan.
Abstract
Hepatitis B virus (HBV) infection is still one kind of the infectious diseases that seriously threaten human health. Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. HBV infection complicated with NAFLD is increasingly common. This review mainly describes the interaction between HBV infection and NAFLD, the interaction between steatosis and antiviral drugs, and the prognosis of HBV infection complicated with NAFLD. Most studies suggest that HBV infection may reduce the incidence of NAFLD. NAFLD can promote the spontaneous clearance of hepatitis B surface antigen (HBsAg), but whether it affects antiviral efficacy has been reported inconsistently. HBV infection combined with NAFLD can promote the progression of liver fibrosis, especially in patients with severe steatosis. The outcome of HBV infection combined with NAFLD predisposing to the progression of HCC remains controversial.
摘要
乙型肝炎病毒（HBV）感染仍然是严重威胁人类健康的传染病之一。非酒精性脂肪性肝病（NAFLD）已成为全球最常见的慢性肝病。HBV感染合并NAFLD越来越常见。本综述主要描述HBV感染与NAFLD之间的相互作用、脂肪变性与抗病毒药物之间的相互作用，以及HBV感染合并NAFLD的预后。大多数研究表明，HBV感染可能降低NAFLD的发病率。NAFLD可促进乙型肝炎表面抗原（HBsAg）的自发清除，但关于其是否影响抗病毒疗效的报道并不一致。HBV感染合并NAFLD可促进肝纤维化进展，尤其是在重度脂肪变性患者中。HBV感染合并NAFLD易导致肝癌进展的结局仍存在争议。
相似文献
1
Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis.乙型肝炎病毒感染合并非酒精性脂肪性肝病：相互作用与预后
Heliyon. 2023 Jan 20;9(1):e13113. doi: 10.1016/j.heliyon.2023.e13113. eCollection 2023 Jan.
2
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.使用聚乙二醇化干扰素-α2a作为一线治疗以及第12周乙肝病毒DNA/乙肝表面抗原停药规则对HBeAg阴性慢性乙型肝炎进行个体化治疗：一项成本效益分析
Antivir Ther. 2013;18(4):623-33. doi: 10.3851/IMP2555. Epub 2013 Mar 13.
3
Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B.对于初治的乙肝e抗原阳性慢性乙型肝炎患者，替诺福韦优于恩替卡韦。
J Clin Exp Hepatol. 2021 Jan-Feb;11(1):37-44. doi: 10.1016/j.jceh.2020.05.003. Epub 2020 May 19.
4
Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.乙型肝炎和非酒精性脂肪性肝病患者肝癌的临床特征和生存结局的差异。
J Chin Med Assoc. 2021 Jun 1;84(6):606-613. doi: 10.1097/JCMA.0000000000000530.
5
Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease.基线期肝细胞气球样变是慢性乙型肝炎合并非酒精性脂肪性肝病患者发生不良事件的危险因素。
World J Hepatol. 2023 Feb 27;15(2):237-254. doi: 10.4254/wjh.v15.i2.237.
6
INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.印度肝脏研究学会关于印度乙型肝炎病毒感染预防、诊断和管理的立场声明：安达曼声明
J Clin Exp Hepatol. 2018 Mar;8(1):58-80. doi: 10.1016/j.jceh.2017.12.001. Epub 2017 Dec 16.
7
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.对于慢性乙型肝炎患者，从恩替卡韦或核苷（酸）联合治疗转换为替诺福韦艾拉酚胺治疗。
Liver Int. 2020 Jul;40(7):1578-1589. doi: 10.1111/liv.14482. Epub 2020 Apr 30.
8
Saturated Fatty Acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response.饱和脂肪酸通过Toll样受体4介导的天然免疫反应抑制慢性乙型肝炎病毒感染合并非酒精性脂肪性肝病中的病毒复制。
Hepat Mon. 2015 May 23;15(5):e27909. doi: 10.5812/hepatmon.15(5)2015.27909. eCollection 2015 May.
9
Current Trend in Antiviral Therapy for Chronic Hepatitis B.目前慢性乙型肝炎抗病毒治疗的趋势。
Viruses. 2022 Feb 21;14(2):434. doi: 10.3390/v14020434.
10
A Meta-Analysis of How Nonalcoholic Fatty Liver Disease Affect Antiviral Treatment of Patients with e Antigen-Positive Chronic Hepatitis B.非酒精性脂肪性肝病如何影响e抗原阳性慢性乙型肝炎患者抗病毒治疗的Meta分析
Emerg Med Int. 2022 Oct 3;2022:4774195. doi: 10.1155/2022/4774195. eCollection 2022.
引用本文的文献
1
Reduced Predictive Performance of the FIB-4 Index in Chronic Hepatitis B Patients With Concurrent Metabolic Dysfunction-Associated Liver Disease.FIB-4指数在合并代谢功能障碍相关肝病的慢性乙型肝炎患者中预测性能降低。
J Viral Hepat. 2025 Oct;32(10):e70071. doi: 10.1111/jvh.70071.
2
Impact of Socio-Economic, Behavioural and Clinical Factors on Liver Disease Progression in Individuals With HIV and Hepatitis B.社会经济、行为和临床因素对合并感染艾滋病毒和乙型肝炎患者肝病进展的影响
Liver Int. 2025 Jul;45(7):e70191. doi: 10.1111/liv.70191.
3
A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure.一项关于干扰素治疗慢性乙型肝炎合并代谢相关脂肪性肝病以实现临床治愈的前瞻性、多中心队列研究的研究方案。
Front Public Health. 2025 Mar 14;13:1546182. doi: 10.3389/fpubh.2025.1546182. eCollection 2025.
4
Clinical profiles and their interaction of concurrent metabolic associated steatotic liver disease and hepatitis B virus infection.代谢相关脂肪性肝病与乙型肝炎病毒感染并存的临床特征及其相互作用
World J Hepatol. 2024 Dec 27;16(12):1429-1440. doi: 10.4254/wjh.v16.i12.1429.
5
Correlation Between Transient Elastography and Non-invasive Biomarker Scores for the Detection of Liver Fibrosis.瞬时弹性成像与用于检测肝纤维化的非侵入性生物标志物评分之间的相关性
Cureus. 2024 Nov 2;16(11):e72892. doi: 10.7759/cureus.72892. eCollection 2024 Nov.
6
Prospective appraisal of clinical diagnostic algorithms for hepatocellular carcinoma surveillance in Chinese patients with chronic hepatitis B infection.前瞻性评估中国慢性乙型肝炎感染患者肝细胞癌监测的临床诊断算法。
Sci Rep. 2024 Nov 22;14(1):28996. doi: 10.1038/s41598-024-80257-w.
7
Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease.诊断准确性的 FibroScan-AST (FAST) 评分、非酒精性脂肪性肝纤维化评分 (NFS)、FibroScan 和肝纤维化指数 (FIB-4) 在识别代谢相关脂肪性肝病合并慢性乙型肝炎患者的纤维化非酒精性脂肪性肝炎。
Ann Med. 2024 Dec;56(1):2420858. doi: 10.1080/07853890.2024.2420858. Epub 2024 Oct 26.
8
Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study.并发慢性乙型肝炎和代谢功能障碍相关肝病的独特临床和病毒学特征：一项基于人群队列研究的见解
J Clin Med. 2024 Sep 21;13(18):5608. doi: 10.3390/jcm13185608.
9
Prevalence of Non-Alcoholic Fatty Liver Disease and Its Impact on Fibrosis Risk in Inactive Chronic Hepatitis B Patients: Insights from a Cross-Sectional Study.非酒精性脂肪性肝病在慢性乙型肝炎非活动期患者中的患病率及其对纤维化风险的影响：一项横断面研究的见解
J Clin Med. 2024 Aug 12;13(16):4738. doi: 10.3390/jcm13164738.
10
The hepatic steatosis, steatohepatitis and metabolic dysfunction: distinct roles in hepatocellular carcinoma occurrence in chronic hepatitis B patients.肝脂肪变性、脂肪性肝炎与代谢功能障碍：在慢性乙型肝炎患者肝细胞癌发生中的不同作用
Hepatol Int. 2024 Aug;18(4):1338-1339. doi: 10.1007/s12072-024-10675-5. Epub 2024 Jun 27.
本文引用的文献
1
Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B.PNPLA3 p.I148M和肝脂肪变性对慢性乙型肝炎患者肝细胞癌长期预后及HBsAg血清清除的影响
J Hepatocell Carcinoma. 2022 Apr 11;9:301-313. doi: 10.2147/JHC.S355540. eCollection 2022.
2
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯治疗初治慢性乙型肝炎的疗效和安全性。
Liver Int. 2022 Jul;42(7):1517-1527. doi: 10.1111/liv.15261. Epub 2022 Apr 3.
3
Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.脂肪肝进展算法和脂肪变性、活动度及纤维化评分在评估非酒精性脂肪肝对未经治疗的慢性乙型肝炎患者影响中的应用。
Front Cell Infect Microbiol. 2022 Jan 17;11:733348. doi: 10.3389/fcimb.2021.733348. eCollection 2021.
4
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺对乙型肝炎患者血脂谱的影响。
PLoS One. 2022 Jan 20;17(1):e0261760. doi: 10.1371/journal.pone.0261760. eCollection 2022.
5
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.替诺福韦艾拉酚胺治疗可能不会恶化慢性乙型肝炎患者的血脂情况：一项倾向评分匹配分析。
Clin Mol Hepatol. 2022 Apr;28(2):254-264. doi: 10.3350/cmh.2021.0314. Epub 2021 Dec 28.
6
Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan.四川地区共存疾病患者的肝功能酶和血脂谱异常：一项人群研究。
Biosci Rep. 2021 Dec 22;41(12). doi: 10.1042/BSR20211769.
7
Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors.肝脂肪变性和 2 型糖尿病的发展：慢性乙型肝炎和病毒特异性因素的影响。
J Formos Med Assoc. 2022 Aug;121(8):1478-1487. doi: 10.1016/j.jfma.2021.10.014. Epub 2021 Nov 8.
8
Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection.慢性乙型肝炎感染患者抗病毒治疗期间生化反应的比较。
Liver Int. 2022 Feb;42(2):320-329. doi: 10.1111/liv.15086. Epub 2021 Nov 12.
9
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide.治疗乙肝患者换用替诺福韦艾拉酚胺后体重的变化。
J Formos Med Assoc. 2022 Jul;121(7):1273-1282. doi: 10.1016/j.jfma.2021.09.009. Epub 2021 Oct 5.
10
Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients.肝脂肪变在 HBeAg 阴性慢性乙型肝炎患者乙肝表面抗原血清学转换中的作用。
Int J Clin Pract. 2021 Dec;75(12):e14899. doi: 10.1111/ijcp.14899. Epub 2021 Sep 29.
Zotero 插件